clinical trial · NCT07934017
A Study of SL-325 in Participants With Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS)SL-325Placebo
brief summary
The primary purpose of this study is to evaluate the efficacy of SL-325 in adult participants with Hidradenitis Suppurativa. The study consists of a screening period of up to 5 weeks, a 16-week primary treatment period, 36-week extension period, and a follow-up period of up to 12 weeks.
started
Jan 1, 2027
primary completion
Feb 1, 2028
completion
Dec 1, 2028
last updated
Nov 12, 2026
official title
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SL-325 in Participants With Moderate to Severe Hidradenitis Suppurativa (RECEPTIVE-HS1)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol